Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
GHK-Cu3 residuesGHKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: GHK:Cu, copper tripeptide-1, copper peptide GHK
Three amino acids and a copper ion. That's the entire structure of the GHK-Cu peptide, a copper tripeptide the body already produces but loses roughly 60% of by age 60. Pickart and colleagues mapped its gene expression reach to over 4,000 human genes [1], touching collagen, elastin, inflammation, and antioxidant pathways all at once. No human injectable RCT exists yet. That gap matters. But community experience across 100 to 200+ Reddit threads and biohacker forums consistently describes improved skin texture by week four, faster wound closure, and early hair regrowth at the temples. Available as both injectable and topical, GHK-Cu sits at the intersection of decades-old science and a still-growing user base.
Four thousand genes. That's the number GHK-Cu flips toward repair when it binds to human cells, according to gene expression profiling by Pickart's group (26236730)[1]. The GHK-Cu peptide (glycyl-L-histidyl-L-lysine copper(II), also written GHK:Cu or copper tripeptide-1) is a naturally occurring copper peptide found in human plasma, saliva, and urine. Plasma levels sit around 200 ng/mL at age 20 and drop to roughly 80 ng/mL by age 60. The mechanism is broad. GHK-Cu upregulates collagen I, III, and V synthesis, boosts elastin and decorin production, and recruits immune and endothelial cells to damaged tissue. The copper ion itself is required for enzymatic processes in wound remodeling. In 2024, Bian and colleagues confirmed anti-fibrotic activity in a silicosis lung model with human biomarker data [2], expanding the peptide's research footprint beyond skin. In practice, two routes dominate. Topical formulations (1 to 3% concentration) have cosmetic safety data going back decades; small clinical trials (n = 41 to 71) showed improved skin density and fine line reduction. Injectable use (0.5 to 2 mg/day subcutaneous) has no published dose-finding trial in humans but has one of the largest community evidence bases of any anti-aging peptide. Reports across r/Peptides, r/Biohackers, and practitioner networks describe improved skin firmness by weeks four to six; sentiment runs at 4.2 out of 5. The honest limitation: all mechanistic data is in vitro or murine. Pro-angiogenic activity flagged by the NCI raises an unresolved theoretical oncology concern. GHK-Cu is classified as research-only and is not FDA-approved for any indication.
GHK-Cu works at the gene expression level. Microarray studies from Pickart's lab identified upregulation of over 4,000 genes and suppression of destructive pathways when human cells are exposed to the peptide [1]. That's not a vague claim; the gene list is published and includes collagen I, III, and V, elastin, decorin (the scaffolding protein collagen needs to organize correctly), and multiple antioxidant genes [3]. The copper(II) ion is load-bearing. Without it, the tripeptide GHK has limited biological activity. Copper activates lysyl oxidase, an enzyme required for collagen and elastin crosslinking. It also supports superoxide dismutase activity, which ties into the antioxidant gene data. At the tissue level, GHK-Cu attracts both immune cells and endothelial cells to wound sites. This dual recruitment accelerates debris clearance and new blood vessel formation (angiogenesis). Pickart and Margolina described this in a 2008 review [4] as a "reset" toward a younger tissue repair program. Recent work has extended these findings. Bian and colleagues showed GHK-Cu attenuates lung fibrosis in a silicosis model via the PRDX6/GPX4 pathway (Redox Biology, 2024)[2]. A 2025 review explored applications in inflammatory bowel disease [5]. The peptide's reach keeps expanding, but the core mechanism remains the same: copper-dependent gene modulation that shifts tissue toward repair.
Preclinical evidence is strong for collagen stimulation, wound healing, and gene expression modulation (4,000+ genes). Human clinical data is limited to small topical cosmetic trials. No human RCTs for injectable route exist. 2024–2025 research expanded applications to pulmonary protection [2] and IBD [5]. Core collagen and elastin mechanisms are well-validated in vitro and in animal models.
Pickart et al.: multiple landmark studies on GHK-Cu gene expression modulation (PMID 25789553, 26236730). Most recent: PMID 38879894 (Bian Y et al., Redox Biology, Sep 2024): GHK-Cu attenuates lung fibrosis in silicosis via PRDX6 pathway; includes human biomarker data.
No human RCTs for injectable route. Topical clinical trials are small (n=41–71), non-blinded, or lack placebo arms. Nearly all mechanistic data is in vitro or murine. Skin penetration of topical GHK-Cu is limited due to hydrophilicity: liposomal delivery unmeasured (PMID 39795193). Pro-angiogenic activity raises theoretical oncology concern (NCI) that is unresolved in humans.
Highly positive community reception. Consistently rated one of the most tolerated anti-aging peptides. Skin texture improvement at 4–6 weeks is the most reproducible reported outcome. Hair regrowth and wound healing are common secondary uses. Topical overuse ("copper uglies") is the most-discussed adverse pattern.
Science and community agree on core benefits (collagen, wound healing, skin rejuvenation) and the topical route. Divergence exists on injectable dosing: community doses 1–3 mg/day SubQ without a published human dose-finding trial to support any specific number. Community primarily uses injectable for systemic anti-aging while published research focuses on topical and localized wound healing. Pro-angiogenic concern is under-discussed in community protocols.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mg | Daily |
| Moderate | 2,500mcg | Daily |
| Aggressive | 3mg | Daily |
The blue-green color when you reconstitute is not contamination. It's the copper(II) ion doing exactly what it should. If your solution is colorless after proper reconstitution, that's actually the problem: copper may have dissociated, and potency drops with it. Reconstitution math for common vial sizes: a 5 mg vial plus 2 mL bacteriostatic water gives you 2,500 mcg/mL. A 1 mg dose (1,000 mcg) equals 0.4 mL, which is 40 units on a U-100 insulin syringe. For the 50 mg vial plus 5 mL bacteriostatic water, you get 10,000 mcg/mL; a 1 mg dose is just 0.1 mL or 10 units. Store reconstituted vials in a dark refrigerator. Copper ions are photosensitive. Expect two to three weeks of usable shelf life. Start at 500 mcg/day for injectable and titrate up over two weeks. Evening injection is the community standard. Rotate abdominal sites and don't hit the same spot more than once per week; lipodystrophy from poor rotation is a real and visible consequence.
Cycle 4-8 weeks for injectable use. Topical application can be used continuously without cycling.
Injectable GHK-Cu cycling serves two purposes: (1) copper accumulation management: daily parenteral copper peptide adds measurable systemic copper load; while 1–2 mg/day produces copper exposure well below toxic thresholds, continuous long-term use without monitoring creates theoretical accumulation risk; (2) pathway sensitivity: GHK-Cu modulates 4,000+ genes and activates multiple repair pathways; periodic off cycles are speculated to maintain sensitivity, though no human data confirms desensitization occurs. Topical GHK-Cu at ≤3% does not require cycling due to minimal systemic copper absorption.
Or use the universal Peptide Calculator for any peptide.
Expected: Improved skin texture and hydration by weeks 2–4. Visible fine line reduction and improved firmness by weeks 6–8. Collagen remodeling continues through week 12.
Monitor: Discontinue if paradoxical skin worsening occurs (copper uglies: accelerated sagging or wrinkling). This indicates MMP-1 overactivation; reduce concentration and frequency.
Gather supplies: GHK-Cu lyophilized vial, bacteriostatic water, alcohol swabs, U-100 insulin syringe (29 to 31 gauge, 0.5 inch needle).
Clean both vial stoppers with alcohol swabs and let dry.
For a 5 mg vial, use 2 mL. For a 50 mg vial, use 5 mL.
Do not spray directly onto the powder. Swirl gently until dissolved. The solution will turn blue-green; this is normal and expected.
At 5 mg in 2 mL: 1 mg (1,000 mcg) = 40 units on the syringe. At 50 mg in 5 mL: 1 mg = 10 units on the syringe.
Draw your dose, removing air bubbles by tapping the syringe barrel.
Pinch a fold of abdominal skin (or near your target area for localized effects). Insert needle at a 45-degree angle. Inject slowly.
Withdraw the needle, apply light pressure with an alcohol swab. If you experience copper sting, hold a cold compress for 60 seconds.
Map at least six to eight abdominal locations and cycle through them. No site more than once per week.
Store the reconstituted vial upright in a dark refrigerator (2 to 8 degrees Celsius). Use within two to three weeks.
Standard systemic: 0.5–2 mg/day. Peri-target SubQ (near scalp for hair, face perimeter for skin) uses same dose with smaller volume and finer needle (31G).
Estimated SC bioavailability ~90–95%. Rapid plasma clearance (~1 hour half-life) but cellular effects persist. Evening injection preferred. No more than 1 injection per site per week to prevent lipodystrophy.
1–3% concentration standard; up to 5% in clinical formulations. Skin penetration is limited by hydrophilicity: microneedling or liposomal encapsulation significantly enhances delivery.
No meaningful systemic copper load at standard concentrations. "Copper uglies" risk at high concentrations or aggressive post-microneedling use. MMP-1 upregulation may outpace collagen synthesis. Can be used continuously (no cycling required) at ≤3% concentration.
Apply 0.5–2% GHK-Cu serum immediately post-microneedling (0.5–1 mm needle depth). Wait 48–72 hours minimum in beginners to assess copper irritation response on disrupted skin barrier.
Do not exceed 2% concentration immediately post-microneedling. Disrupted skin barrier allows excess copper penetration and amplifies MMP-1 upregulation risk. Space microneedling sessions 3–4 weeks apart.
Core GLOW blend: GHK-Cu provides ECM remodeling and collagen synthesis; BPC-157 provides vascular support and cytoprotection. Complementary mechanisms for skin, wound, and tissue healing.
GHK-Cu 1 mg/day SubQ + BPC-157 250 mcg/day SubQ, same cycle length
TB-500 handles cytoskeletal reorganization and cell migration; GHK-Cu handles ECM collagen remodeling. Complementary anti-fibrotic and repair mechanisms.
GHK-Cu 1 mg/day SubQ + TB-500 2 mg, 2–3x/week SubQ
Longevity stack: Epithalon works via telomerase activation and epigenetic mechanisms; GHK-Cu via gene expression and collagen. Additive anti-aging mechanisms targeting different pathways.
GHK-Cu 500 mcg–1 mg/day + Epithalon 10 mg/day for 10-day Epithalon pulse cycles
Mitochondrial and anti-aging synergy. NAD+ supports cellular energy and sirtuin pathway; GHK-Cu modulates repair gene expression. Combined in longevity protocols targeting multiple aging mechanisms.
GHK-Cu 500 mcg–1 mg/day SubQ + NAD+ 100–500 mg IV or SubQ
Competitive inhibition at copper transport sites. High-dose zinc displaces copper in transporter binding, reducing GHK-Cu cellular uptake and bioavailability.
Directly chelate the copper ion in GHK-Cu, reducing bioavailability by 60–80% and unpredictably altering free copper levels. Critical drug interaction.
Do not combineHigh-concentration ascorbic acid chelates copper ions, reducing topical GHK-Cu activity. Separate topical application by at least 2 hours.
Pricing updated 2026-04-09
The most serious concern with GHK-Cu is its pro-angiogenic activity. The NCI flagged this years ago: a peptide that promotes new blood vessel formation could, in theory, support tumor vascularization. No human case has confirmed this, but no study has ruled it out either. Anyone with an active malignancy should not use GHK-Cu without oncologist clearance. Copper toxicity is the second concern worth taking seriously. At typical community doses (1 to 2 mg/day subcutaneous), the copper load stays well below toxic thresholds. But continuous long-term use without lab monitoring creates an accumulation risk. Wilson's disease, hemochromatosis, and any copper metabolism disorder are absolute contraindications. Symptoms of copper excess include nausea, metallic taste, and jaundice; if these appear, stop immediately and get serum copper checked. Published side effects in topical trials are mild. Skin irritation, redness, and occasional contact sensitivity at higher concentrations. The more interesting adverse pattern comes from the community: "copper uglies." This is paradoxical skin worsening (sagging, accelerated wrinkling) caused by MMP-1 matrix metalloproteinase upregulation outpacing collagen synthesis. It happens most often with topical overuse or aggressive post-microneedling application. The fix is simple: drop to 1% concentration and wait 48 to 72 hours after microneedling before applying. Injectable side effects are dominated by injection site reactions. Burning and stinging from the copper ions is the number one complaint in community threads. Diluting with more bacteriostatic water, using a 31-gauge needle, and applying a cold compress for 60 seconds post-injection helps. Site rotation matters; no location should get more than one injection per week. Poor rotation leads to lipodystrophy (localized fat atrophy), which is harder to reverse than it sounds. At doses above 1.5 mg/day, some users report nausea and metallic taste. These are dose-dependent and resolve with reduction. Reconstituted stability is limited to two to three weeks refrigerated. Potency drops 15 to 30% by week four according to community tracking. The mcg versus mg calculation error is a real hazard for beginners; GHK-Cu vials are labeled in mg but doses are discussed in mcg. 1 mg equals 1,000 mcg. Getting this wrong by a factor of 1,000 is not theoretical; it's the most common beginner mistake in the community. Contraindications: Wilson's disease or copper metabolism disorders. Known hypersensitivity to GHK-Cu or copper compounds. Pregnancy or breastfeeding (no safety data). Hemochromatosis. Active malignancy without oncologist clearance. Severe kidney or liver dysfunction. Drug interactions: copper-chelating agents (penicillamine, trientine) reduce bioavailability by 60 to 80%. Zinc above 50 mg/day competes at copper transport sites. High-concentration topical vitamin C (15%+) chelates copper; separate application by two or more hours. Immunosuppressants may interact with the healing response; consult a prescriber.
Verify GHK-Cu dosing and safety with a second opinion
GHK-Cu is a simple tripeptide (Gly-His-Lys + Cu²⁺) that is relatively straightforward to synthesize, reducing complex adulterant risk. However, injectable GHK-Cu from research vendors is not produced under sterile conditions (not USP 797 compliant), creating endotoxin and sterility risks. The compounding pharmacy channel is in regulatory flux (removed from Category 2 on April 15, 2026; PCAC review begins July 2026; compounding access not yet available). The mcg/mg dosing confusion and topical "copper uglies" risk are behavioral quality risks.
| Test | When | Target |
|---|---|---|
| Serum copper | Baseline; recheck at 8 weeks if running extended or high-dose injectable cycles (>1.5 mg/day) | 70–140 mcg/dL (adult normal) |
| Ceruloplasmin | Baseline if Wilson's disease or copper metabolism disorder is suspected | 15–60 mg/dL |
| Liver function panel (ALT, AST, bilirubin) | Baseline for advanced protocols; 8-week check if running high-dose or extended cycles | ALT <56 U/L, AST <40 U/L (lab-specific ranges apply) |
| Serum zinc | Baseline if taking zinc supplements at >25 mg/day | 60–120 mcg/dL |
Injectable GHK-Cu adds systemic copper load; monitoring confirms copper remains within normal range and accumulation has not occurred
Ceruloplasmin is the primary copper transport protein; low ceruloplasmin indicates impaired copper handling and is a contraindication to GHK-Cu use
Copper accumulation is hepatotoxic at excess levels; liver enzymes provide early warning. Also relevant given GHK-Cu modulation of hepatic gene expression.
High-dose zinc (>50 mg/day) competitively inhibits copper transport and reduces GHK-Cu efficacy; adjust zinc supplementation if low response is observed
Initial cellular signaling begins. Gene expression shifts toward repair pathways. Skin may feel slightly more hydrated. No visible changes yet.
Early improvements in skin texture and tone. Minor wounds and blemishes heal faster. Collagen synthesis is ramping up at the cellular level.
Noticeable reduction in fine lines. Skin appears firmer and more elastic. Hair shedding may decrease in those using for hair regrowth.
Peak results for an 8-week injectable cycle. Visible improvement in wrinkles, skin firmness, and wound healing. Some users report early hair regrowth at the temples or crown.
Benefits persist due to sustained collagen remodeling. Topical GHK-Cu can be continued during the off period to maintain skin-level results.
Weeks 1 to 2 (Cellular Signaling Onset): Gene expression changes begin within hours. Repair genes, collagen I/III/V, and elastin pathways activate at the cellular level. Nothing visible yet. Most users notice their skin feels slightly more hydrated, and small injection-site nicks heal faster than expected. The blue-green solution color surprises first-timers, but it confirms the copper-peptide complex is intact. Expect injection site burning from the copper ions; mild redness is common. Nausea at doses above 1.5 mg is rare. Weeks 2 to 4 (Early Tissue Response): Collagen synthesis is ramping up. Elastin deposition is underway. Hair follicle miniaturization signals may start to reverse. Community users describe an improved skin "glow" and noticeably faster healing of minor wounds and blemishes. Topical users report more even skin tone. Hair shedding may slow down. Injection site reactions typically normalize by this point if you're rotating properly. Some users report occasional metallic taste at higher doses. Weeks 4 to 6 (Visible Skin Changes): This is the most consistent benefit window in community reports. Skin feels firmer. Fine lines are visibly reduced. Texture is smoother. Some users see early hair regrowth at the temples or crown. Topical trial data supports measurable increases in skin density and elasticity during this timeframe. Weeks 6 to 8 (Peak Cycle Results): Maximum collagen remodeling within the cycle. Anti-fibrotic effects peak. Gene expression changes are fully established. Wrinkle reduction and skin firmness hit their best. Stacked users running the GLOW blend (BPC-157 and TB-500) report more dramatic results. Watch for lipodystrophy if you've been lazy with site rotation. Post-cycle, 4-week off (Consolidation): Collagen remodeling is slow by nature. Benefits persist four to eight weeks after stopping because the ECM changes are structural, not pharmacological. Most users maintain visible improvements through the entire off period. Topical GHK-Cu at 2% or lower is commonly continued during the break for skin maintenance.
Gene expression modulation begins within hours of administration. Upregulation of repair genes, collagen I/III/V, and elastin synthesis initiated at the cellular level. No macroscopic changes expected.
Skin feels slightly more hydrated. Some users notice injection site heals faster than usual. No visible skin changes yet. Blue-green solution color often surprises first-time users (it is normal).
Collagen synthesis ramping up. Elastin deposition beginning. Wound healing acceleration measurable histologically. Hair follicle miniaturization signals may begin to reverse.
Improved skin texture and "glow." Minor wounds and blemishes heal noticeably faster. Topical users report better skin tone evenness. Hair shedding may decrease.
Measurable increases in skin density and elasticity based on topical trial data. Fine line reduction becomes histologically measurable.
Most consistent benefit window: skin firmer, fine lines reduced, texture smoother. First reports of early hair regrowth appearing at temples or crown.
Maximum collagen remodeling within the cycle. Anti-fibrotic effects peak. Gene expression changes fully established.
Visible wrinkle reduction and skin firmness peak. Wound/scar remodeling visibly improved. Stacked users (GLOW blend with BPC-157/TB-500) report more dramatic outcomes.
Collagen remodeling is slow: benefits persist 4–8 weeks post-cycle due to sustained ECM changes. Gene expression returns toward baseline gradually.
Most users maintain visible improvements through the off period. Topical GHK-Cu commonly continued during off cycle for skin maintenance at ≤2% concentration.
Source: Estimated from plasma degradation studies; rapid enzymatic cleavage by peptidases gives a ~30-60 min range
Loading the interactive decay curve.
GHK-Cu is classified as a research chemical in the United States. It has no FDA approval for any indication. Sale is permitted for in vitro research purposes only; "not for human consumption" labeling is standard from research vendors. Compounding pharmacies can prepare injectable GHK-Cu under a physician's prescription. However, injectable GHK-Cu was on the FDA Category 2 list until April 15, 2026, when HHS removed it along with 11 other peptides. PCAC review begins July 2026. Compounding pharmacy access is not yet available. GHK-Cu is not on the WADA prohibited substances list as of 2026. Topical GHK-Cu products are sold as cosmetic ingredients (copper tripeptide-1 per INCI) and face fewer regulatory restrictions. They do not require a prescription. For injectable sourcing, research vendors provide lyophilized powder without sterility or endotoxin testing. Compounding pharmacies operating under USP 797 standards and PCAB accreditation provide sterile, tested product at a higher price point. This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before using any peptide product.
Peptide Schedule Research TeamReviewed Apr 202614 Citations
